We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

UROY:NASDAQUranium Royalty Corp. Analysis

Data as of 2026-05-07 - not real-time

$3.96

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Uranium Royalty Corp. (UROY) is trading at $3.96, comfortably above its 20‑day (3.77), 50‑day (3.73) and 200‑day (3.76) simple moving averages, indicating short‑term momentum. The RSI sits at 56, suggesting neutral overbought/oversold conditions, while the MACD histogram is positive (0.034) and the MACD signal is bullish, reinforcing a modest upside bias. Support sits at $3.485 and resistance at $4.20, leaving the stock near the lower half of its range.
Fundamentally, the company is severely undervalued by discounted cash‑flow analysis, with a fair‑value estimate of $10.46 – more than double the current price, yielding a ~14% upside relative to analyst targets and a >150% upside versus intrinsic value. The recent agreement to acquire Sweetwater Royalties (≈$1.1 bn) and the Raymond James upgrade to Outperform with a new price target of C$6.25 provide a concrete growth catalyst. However, the stock exhibits high beta (≈2.0), 30‑day volatility of 60%, and decreasing volume, all of which flag elevated market risk.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish MACD and price above short‑term SMAs
  • Acquisition of Sweetwater Royalties as a catalyst
  • Current price well below DCF fair value

Medium Term

1–3 years
Neutral
Model confidence: 8/10

Key Factors

  • Integration of Sweetwater assets driving revenue growth
  • Uranium price outlook supporting royalty earnings
  • Persistent high volatility and beta moderating upside

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Long‑term nuclear energy demand underpinning uranium royalties
  • Strategic land and royalty portfolio across multiple jurisdictions
  • Significant intrinsic value gap (price vs DCF fair value)

Key Metrics & Analysis

Financial Health

Revenue Growth416400.00%
Profit Margin8.03%
P/E Ratio132.0
ROE1.29%
ROA0.43%
Debt/Equity0.04
P/B Ratio2.1
Op. Cash Flow$39.9M
Free Cash Flow$38.0M
Industry P/E20.3

Technical Analysis

TrendNeutral
RSI56.4
Support$3.48
Resistance$4.20
MA 20$3.77
MA 50$3.73
MA 200$3.76
MACDBullish
VolumeDecreasing
Fear & Greed Index90.93

Valuation

Fair Value$10.46
Target Price$4.52
Upside/Downside14.06%
GradeUndervalued
TypeGrowth

Risk Assessment

Beta2.00
Volatility60.35%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.